CAS: 873697-71-3; Methyl 4-(2-Fluoro-3-(3-(6-Methylpyridin-3-yl)Ureido)Benzyl)Piperazine-1-Carboxylate

该化合物是一种新颖的小分子,被归类为心肌膜活化器,主要被调查其治疗心衰竭的潜力.它通过有选择地提高心脏肌肉的紧凑性,而不增加细胞内钙含量,有助于提高心脏输出,同时尽量减少心律不全的风险.该化合物的特点是其独特的行动机制,它针对的是近氧运动蛋白,从而提高心肌收缩的效率.Omecamtiv mecarbil是各种临床试验的主体,表明它有能力提高心功能,减少弹射分数的病人的心脏功能.其药理动力学特征显示,中度吸收和半衰期允许一次做剂量.此外,必须指出,尽管在进行中的研究中继续评估蛋白色素运动的长期影响和安全特征.

结构式图片

欧盟法规

REACH注册

上下游产品

CAS号732245-99-7 5-异氰酸酯-2-甲基吡啶 | CAS号873697-70-2 methyl 4-(3-ami... | CAS号3430-13-5 5-溴-2-甲基吡啶 | CAS号1309439-44-8 (2-methylpyridi... | CAS号1309439-45-9 methyl 4-(3-chl... | CAS号50606-31-0 哌嗪-1-羧酸甲酯

合成工艺路线路线简述

  • 合成目标产物 Omecamtiv Mecarbil 主要起始原料 5-Isocyanato-2-Methyl-Pyridine And 4-(3-Amino-2-Fluoro-Benzyl)-Piperazine-1-Carboxylic Acid Methyl Ester
  • 1628206-34-7 + 873697-70-2 = 873697-71-3
    反应条件:1.1 Reagents: Diisopropylethylamine Solvents: Acetonitrile,Tetrahydrofuran; 21 H,57 °C
    标题:Development Of A Factory Process For Omecamtiv Mecarbil,A Novel Cardiac Myosin Activator
    作者:Caille,Seb; Allgeier,Alan M.; Bernard,Charles; Correll,Tiffany L.; Cosbie,Andrew; Et Al
    参考文献:Organic Process Research & Development 日期:2019 卷标:23(8) 页码:1558-1567]

    732245-99-7 + 873697-70-2 = 873697-71-3
    反应条件:1.1 Solvents: Acetone; 4 Min,40 +/- 5 °C; 5 Min,40 °C -> Reflux; 250 Min,Reflux; 460 Min,Reflux -> 30 °C; 5 H,< 30 °C
    标题:Discovery Of Omecamtiv Mecarbil The First,Selective,Small Molecule Activator Of Cardiac Myosin
    作者:Morgan,Bradley P.; Muci,Alexander; Lu,Pu-Ping; Qian,Xiangping; Tochimoto,Todd; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2010 卷标:1(9) 页码:472-477]

    1309439-45-9 + 1309439-44-8 = 873697-71-3
    反应条件:1.1 Catalysts: Palladium Diacetate,Water,[3,6-Dimethoxy-2′,4′,6′-Tris(1-Methylethyl)[1,1′-Biphenyl]-2-Yl]Bis(1,1-Dimethyl... Solvents: Tetrahydrofuran; 4 Min,Rt -> 110 °C1.2 Reagents: Cesium Carbonate; 6 H,Rt -> 65 °C
    标题:Synthesis Of Unsymmetrical Diarylureas Via Pd-Catalyzed C-N Cross-Coupling Reactions
    作者:Breitler,Simon; Oldenhuis,Nathan J.; Fors,Brett P.; Buchwald,Stephen L.
    参考文献:Organic Letters 日期:2011 卷标:13(12) 页码:3262-3265]

    917-61-3 + 1309439-45-9 + 3430-14-6 = 873697-71-3
    反应条件:1.1 Catalysts: Tris(Dibenzylideneacetone)Dipalladium,[3,6-Dimethoxy-2′,4′,6′-Tris(1-Methylethyl)[1,1′-Biphenyl]-2-Yl]Bis(1,1-Dimethyl... Solvents: Toluene; 3 Min,120 °C1.2 Reagents: Phenol,Triethylamine; Rt -> 120 °C; 16 H,120 °C; 120 °C -> Rt1.3 Solvents: Toluene; 15 H,80 °C
    标题:Palladium-Catalyzed Cross-Coupling Of Aryl Chlorides And Triflates With Sodium Cyanate: A Practical Synthesis Of Unsymmetrical Ureas
    作者:Vinogradova,Ekaterina V.; Fors,Brett P.; Buchwald,Stephen L.
    参考文献:Journal Of The American Chemical Society 日期:2012 卷标:134(27) 页码:11132-11135
📜哌嗪-1-羧酸甲酯置于磷酸,5%-Palladium/activated Carbon,氢气,N,N-二异丙基乙胺,Sodium Hydroxide体系中,用 四氢呋喃,甲醇,乙醇,甲基叔丁基醚,水,甲苯,乙腈 作为反应溶剂,10.0~57.0 °C,413.7 Kpa 条件下,反应 34.5H,反应生成 4-[[2-氟-3-[n'-(6-甲基吡啶-3-基)脲基]苯基]甲基]哌嗪-1-羧酸甲酯
参考文献:新型心肌肌球蛋白激活剂omecamtiv Mecarbil的工厂工艺开发
标题:新型心肌肌球蛋白激活剂omecamtiv Mecarbil的工厂工艺开发
摘要:描述了制造新型心脏肌球蛋白活化剂omecamtiv Mecarbil(1)的工厂方法的发展.omecamtiv Mecarbil是通过两个关键片段(苯胺2和氨基甲酸酯4-Hcl)的聚合合成和偶联而制备的,它们用作被掩盖的异氰酸酯.为了能够实际使用苯胺2,设计了相应的硝基芳族化合物的还原反应,以控制潜在的诱变杂质.有效制备2的关键是对8进行苄基溴化,然后对二溴联苯宝石副产物进行选择性脱溴,然后再用5-磷酸烷基化.总的来说,最长的线性序列包括六个步骤,包括最终的成盐步骤,以55%的总收率提供原料药.由于药物的原始游离碱形式在调释制剂中的性能较差,因此开发了一种改进的二盐酸盐水合物形式来帮助提高药物性能和可制造性.
DOI:10.1021/acs.Oprd.9B00200

海关参考信息

专利信息


专利号:US-11702380-B2
优先权日:2021-03-10
标 题:Synthesis of omecamtiv mecarbil
发明人:CAILLE SEBASTIEN; MURRAY JAMES; QUASDORF KYLE; NGUYEN HANNAH; SILVA ELIPE MARIA VICTORIA; ERICSON ARI ELIZABETH
权利人:AMGEN INC
摘要:Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride.

专利号:US-12269811-B2
优先权日:2017-06-30
标 题:Synthesis of omecamtiv mecarbil
发明人:CAILLE SEBASTIEN; QUASDORF KYLE; ROOSEN PHILIPP C; SHI XIANQING; COSBIE ANDREW; WANG FANG; WU ZUFAN; NEERGUNDA ARCHANA; QUAN BIN PETER; GUAN LIANXIU
权利人:AMGEN INC
摘要:Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (1)

专利号:US-2023373955-A1
优先权日:2017-06-30
标 题:Synthesis of omecamtiv mecarbil

专利号:US-2022298099-A1
优先权日:2021-03-10
标题:Synthesis of omecamtiv mecarbil

专利号:TW-202300479-A
优先权日:2021-03-10
标 题:Synthesis of omecamtiv mecarbil

专利号:WO-2022192414-A2
优先权日:2021-03-10
标题:Synthesis of omecamtiv mecarbil

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13. 8(4):329-340. doi: 10.1016/j.jchf.2019.12.001. Epub 2020 Feb 6. 15(2):102-113. doi: 10.2174/1573403X15666181212125024.
4: Zhou S, Liu Y, Huang X, Wu C, Pórszász R. Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future. Front Cardiovasc Med. 2024 Mar 19;11:1337154. doi: 10.3389/fcvm.2024.1337154.
5: Nanasi P, Komaromi I, Gaburjakova M, Almassy J. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results. Curr Med Chem. 2018;25(15):1720-1728. doi: 10.2174/0929867325666171222164320. 25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19. 74(3):155-162. doi: 10.1016/j.ihj.2022.03.005. Epub 2022 Mar 15.

合成参考文献


参考文献:10.1016/j.yjmcc.2011.05.006
摘要:Malik FI, Morgan BP. Cardiac myosin activation part 1: From concept to clinic. Journal of Molecular and Cellular Cardiology. 2011 Oct;51(4):454–61. doi: 10.1016/j.yjmcc.2011.05.006.
参考文献:10.1124/dmd.121.000444
摘要:Trivedi A, Wahlstrom J, Mackowski M, Dutta S, Lee E. Pharmacokinetics, Disposition, and Biotransformation of [14C]Omecamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose. Drug Metab Dispos. 2021 Aug;49(8):619–28. doi: 10.1124/dmd.121.000444.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知